Aclara, Cell Signaling sign licensing deal

Dec. 4, 2003 — Aclara BioSciences Inc. signed a supply and license agreement with Cell Signaling Technology Inc. (CST), according to a news release.


Mountain View, Calif.-based Aclara will use and resell certain reagents made by Beverly, Mass.-based CST in conjunction with Aclara’s microfluidic eTag Assay System. Aclara said its system enables accurate analysis of genes and proteins from limited biological samples and can be used with researchers’ existing equipment.


CST said combining the technologies creates an important discovery application for its antibodies. The company expects that the technology will be critical in advancing cell biology research toward targeted drugs, the release said.


Aclara, listed on Nasdaq, was trading late Thursday morning at 3.45, up from 3.32 Wednesday.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.